Core Insights - Orion Group has published its Financial Statement documents for 2025, which include the Financial Statements, Report by the Board of Directors, Sustainability Statement, and Corporate Governance Statement [1][4] - The Financial Statements comply with the European Single Electronic Format (ESEF) reporting requirements and have been audited by KPMG Oy Ab [2] - The Sustainability Statement adheres to the European Sustainability Reporting Standards (ESRS) and has also been assured by KPMG Oy Ab [3] Financial Performance - In 2025, Orion's net sales reached EUR 1,890 million, reflecting the company's strong market position and operational capabilities [6] Corporate Governance - The Remuneration Report for 2025 has been adopted by the Board of Directors and is available in both Finnish and English [5]

Core Viewpoint - Orion Corporation has established a new Long-term Incentive Program for key personnel, aiming to align the interests of shareholders and key individuals to enhance company value and provide competitive rewards based on share performance [1][2]. Group 1: Long-term Incentive Program Details - The Long-term Incentive Program includes performance share plans launched annually, with a three-year earning period for participants to earn class B shares [1]. - The new plan period for the program is set for the calendar years 2026-2028, with the first plan launched in 2025 covering 2025-2027 [2]. - The maximum reward for the 2026-2028 period is capped at 420,000 class B shares, with a total estimated cost of MEUR 26.5 based on share price averages prior to the plan's launch [4]. Group 2: Performance Criteria and Reward Structure - Rewards will be determined based on the achievement of targets related to operating profit, net sales, pipeline and portfolio development, and ESG performance [3]. - The total reward is limited to three times the participant's annual base salary, with a portion paid in cash to cover tax liabilities [5]. Group 3: Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience, focusing on human and veterinary pharmaceuticals, including proprietary and generic medicines [7]. - In 2025, Orion's net sales reached EUR 1,890 million, and the company employs approximately 4,000 professionals globally [7].

Financial Performance - In Q4 2025, net sales increased by 60.1% to EUR 695.3 million compared to EUR 434.4 million in Q4 2024 [1] - Operating profit for Q4 2025 was EUR 328.1 million, more than tripling from EUR 92.7 million in Q4 2024 [2] - For the full year 2025, net sales reached EUR 1,889.5 million, a 22.5% increase from EUR 1,542.4 million in 2024 [1] - Full year operating profit was EUR 631.6 million, up 51.6% from EUR 416.6 million in 2024 [1] - Basic earnings per share for 2025 were EUR 3.56, a 51.5% increase from EUR 2.35 in 2024 [1] Business Divisions - The Innovative Medicines division saw net sales more than double in Q4 2025, driven by a EUR 180 million milestone and strong Nubeqa® sales [3] - The Branded Products and Generics and Consumer Health divisions also maintained solid growth, supported by high-quality portfolios [4] - The Animal Health division continued to perform well, contributing to overall sales stability [4] Research and Development - Orion initiated a phase 2 trial of ODM-212, a TEAD inhibitor, focusing on rare cancers, with plans to expand the program in 2026 [5] - A second phase 3 trial with levosimendan for pulmonary hypertension was also initiated by partner Tenax [5] Future Outlook - For 2026, net sales are estimated to be between EUR 1,900 million and EUR 2,100 million, with operating profit expected to range from EUR 550 million to EUR 750 million [12] - The growth in 2026 is anticipated to be driven by increasing Nubeqa® royalties and product sales [16] - The Branded Products division is expected to grow, particularly in the Respiratory therapy area and the Easyhaler® product portfolio [17] Dividend Proposal - The Board of Directors proposed a dividend of EUR 1.80 per share for 2025, to be paid in two instalments [7][8] - The first instalment of EUR 0.90 is proposed to be paid on April 2, 2026, and the second instalment on October 27, 2026 [8]

Group 1 - Orion Corporation has converted 62,752 A shares into B shares, which has been officially recorded in the Trade Register on February 3, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,524,740 A shares and 109,609,538 B shares [1] - The total number of votes associated with the company's shares after the conversion is 740,104,338 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Core Viewpoint - Orion Corporation has converted 182,827 A shares into B shares as part of its stock exchange activities, indicating a strategic move to enhance liquidity and shareholder flexibility [1] Group 1 - The conversion of shares took place on January 16, 2026, at 9:30 EET [1] - A total of 182,827 A shares were converted into B shares, reflecting the company's ongoing efforts to manage its capital structure [1]

Financial Statement Release - Orion will publish its Financial Statement Release for 2025 on 12 February 2026 at approximately 12.00 noon EET [1] - The release and related presentation material will be available on the company's website after publishing [1] Webcast and Conference Call - A webcast and conference call for analysts, investors, and media representatives will be held on 12 February 2026 at 14.00 EET [2] - A link to the live webcast will be available on Orion's website, and a recording will be accessible later the same day [2] - Registration is required to join the conference call, with details provided through a specific link [2][3] Company Overview - Orion is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [5] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [5] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [5]

Group 1 - Orion Corporation has converted 182,827 A shares into B shares, with the conversion recorded on January 16, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,587,492 A shares and 109,546,786 B shares [1] - The total number of votes for the company's shares after the conversion is 741,296,626 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has converted 182,827 A shares into B shares, with the conversion recorded on January 16, 2026 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,587,492 A shares and 109,546,786 B shares [1] - The total number of votes for the company's shares after the conversion is 741,296,626 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Core Viewpoint - The Orion Nomination Committee has made recommendations regarding the composition and remuneration of the Board of Directors for the 2026 Annual General Meeting, proposing a total of eight members with specific re-elections and new appointments [1][2]. Board Composition - The proposed Board of Directors will consist of eight members, with six current members re-elected: Kari Jussi Aho, Ari Lehtoranta, Veli-Matti Mattila, Hilpi Rautelin, Henrik Stenqvist, and Karen Lykke Sørensen. New members Minna Maasilta and Sophie Papa are recommended for election [2]. - Veli-Matti Mattila is recommended to continue as Chairman of the Board [2]. - Eija Ronkainen and Maziar Mike Doustdar will not be available for re-election [3]. New Board Members' Background - Minna Maasilta, born in 1986, has a Master of Science (Eng.) and an MBA, with a career in water and environmental engineering, currently serving as Managing Director of Maa- ja vesitekniikan tuki ry [3]. - Sophie Papa, born in 1976, holds multiple degrees including a Bachelor of Arts and a PhD, with extensive experience in medicine and biotechnology, currently a Consulting Venture Partner at RA Capital and Chief Medical Officer at several biotechnology firms [4]. Remuneration Recommendations - The Nomination Committee recommends annual fees: EUR 120,000 for the Chairman, EUR 73,000 for the Vice Chairman, and EUR 60,000 for other members. Additional fees for committee chairpersons are set at EUR 73,000 [6]. - Meeting attendance fees are proposed as EUR 1,200 for the Chairman, EUR 900 for the Vice Chairman, and EUR 600 for other members, with travel expenses covered as per existing practices [7]. - 60% of the annual fees will be paid in cash and 40% in Orion Corporation B shares, with specific amounts allocated for each role [8]. Shareholding Requirements - Board members are required to retain ownership of the Orion Corporation B shares received as fees for two years from the payment date, with conditions for early termination of membership [11]. Additional Information - The Nomination Committee did not provide a recommendation on the remuneration of the Board of Directors, which will be proposed by a shareholder at the Annual General Meeting [12]. - The Nomination Committee consists of members including Hilpi Rautelin as Chair [13].

Core Insights - Orion Corporation estimates that annual net sales of its product Nubeqa® could exceed EUR 1 billion in the future, highlighting its significance as the company's largest product [1] - The company's outlook for 2026 projects net sales between EUR 1,900 million and EUR 2,100 million, with operating profit estimated between EUR 550 million and EUR 750 million [2] - Nubeqa® is identified as the primary driver for net sales and operating profit growth in 2026, with expectations for continued strong sales growth [3] Financial Projections - The estimated net sales for 2026 range from EUR 1,900 million to EUR 2,100 million, indicating a robust growth trajectory for the company [2] - Operating profit for the same period is projected to be between EUR 550 million and EUR 750 million, reflecting the financial health of the company [2] - The outlook does not account for any significant milestone payments, suggesting that the projections are based on core product sales [3] Product Significance - Nubeqa® has become the largest product for Orion, and its financial impact is expected to grow further, prompting the company to provide a sales potential estimate [1] - The sales potential of Nubeqa® is influenced by various factors, including regulatory and market conditions, as well as product indications [1]